These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8830346)

  • 21. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
    Jellinger KA
    Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective potential of spermidine against rotenone induced Parkinson's disease in rats.
    Sharma S; Kumar P; Deshmukh R
    Neurochem Int; 2018 Jun; 116():104-111. PubMed ID: 29501454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
    Muralikrishnan D; Ebadi M
    Brain Res; 2001 Feb; 892(2):241-7. PubMed ID: 11172770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antioxidant therapy in Parkinson's disease.
    Grimes JD; Hassan MN; Thakar J
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):483-7. PubMed ID: 3315149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease.
    Bhattacharjee N; Borah A
    Neurochem Int; 2016 Dec; 101():48-55. PubMed ID: 27732886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
    Przedborski S; Levivier M; Jiang H; Ferreira M; Jackson-Lewis V; Donaldson D; Togasaki DM
    Neuroscience; 1995 Aug; 67(3):631-47. PubMed ID: 7675192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
    Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
    Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
    Kumar S; Dang S; Nigam K; Ali J; Baboota S
    Rejuvenation Res; 2018 Oct; 21(5):464-476. PubMed ID: 29717617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease.
    Chen LW; Wang YQ; Wei LC; Shi M; Chan YS
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):273-81. PubMed ID: 17691984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?
    Damier P; Kastner A; Agid Y; Hirsch EC
    Neurology; 1996 May; 46(5):1262-9. PubMed ID: 8628464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
    Zhao Q; Cai D; Bai Y
    Int J Mol Med; 2013 Oct; 32(4):883-91. PubMed ID: 23877198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy.
    Stoof JC; Winogrodzka A; van Muiswinkel FL; Wolters EC; Voorn P; Groenewegen HJ; Booij J; Drukarch B
    Eur J Pharmacol; 1999 Jun; 375(1-3):75-86. PubMed ID: 10443566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease.
    Koppula S; Kumar H; More SV; Kim BW; Kim IS; Choi DK
    Int J Mol Sci; 2012; 13(8):10608-10629. PubMed ID: 22949883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R; Lecht S; Lazarovici P
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metallothionein, neurotrophins and selegiline in providing neuroprotection in Parkinson's disease.
    Ebadi M; Ramana Kumari MV; Hiramatsu M; Hao R; Pfeiffer RF; Rojas P
    Restor Neurol Neurosci; 1998 Jun; 12(2-3):103-11. PubMed ID: 12671304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.